Although immune checkpoint inhibitor therapies have shown better results in the improvement of OS in ccRCC, the efficacy of anti-PD-1/PD-L1 agents in patients with non-clear RCC (nccRCC) and other unusual tissue subtypes of RCC remains controversial. This evidence concerns the gene CD274 and renal cell adenocarcinoma.